medRxiv preprint doi: https://doi.org/10.1101/2021.10.14.21264978; this version posted October 18, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC 4.0 International license.

1 TITLE: The SARS-CoV-2 infection among students in the University of Porto: a cross-sectional
2 study
3 Paula Meireles¹*, Joana Pinto Costa¹*, Maria João Novais¹, Daniela Miranda¹, Mariana Mendes
4 Lopes¹, Milton Severo¹, Henrique Barros¹,2
5 * equally contributing first authors
6 ¹ EPIUnit–Instituto de Saúde Pública, Universidade do Porto, Rua das Taipas, nº 135, 4050-600

- 7 Porto, Portugal
- 8 ² Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernâni Monteiro, 4200-319
- 9 Porto, Portugal
- 11 ABSTRACT

10

- 12 Introduction
- 13 Incidence based on notified cases of SARS-CoV-2 infection underestimates the real extension
- 14 of the infection. We aimed to quantify SARS-CoV-2 specific antibodies' seroprevalence among
- 15 University students in Porto.
- 16 Methods
- 17 A rapid point of care testing for SARS-CoV-2 specific immunoglobulin (Ig) M and IgG antibodies
- 18 was performed, and a questionnaire was applied to the 6512 voluntary students from
- 19 September to December 2020. We computed the apparent IgM, IgG and IgM or IgG
- 20 prevalence, and the true prevalence and 95% credible intervals (95% CI) using Bayesian
- 21 inference.
- 22 Results
- 23 We found an apparent prevalence (IgM or IgG) of 9.7%, the true prevalence being 7.9% (95%
- Note: This prevalence was significantly higher among males (10.9% vs.9.2%), international was previous.

students (18.1% vs 10.4% local vs 8.8% nationally displaced) and increased with age. Those with a known risk contact, that experienced quarantine, had symptoms, or a previous negative molecular test had a higher seroprevalence. Of the 91 (1.4%) students who reported a molecular diagnosis, 86.7% were reactive for IgM or IgG.

Conclusion

Based on immunological evidence infection was 5.6 times more frequent than if based on a molecular diagnosis. The higher seroprevalence among male, older, and international students emphasizes the importance of identifying particular groups.

Keywords: SARS-CoV-2; seroprevalence; antibodies; University students

INTRODUCTION

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

September and December of 2020.

The infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can follow many distinct courses, with ominous outcomes mostly in the elderly population and no or few unspecific symptoms mainly among young and healthy individuals [1-3]. Real-time Polymerase Chain Reaction (RT-PCR) is the diagnostic "reference standard", but testing strategies changed over the course of the epidemic and varied according to local logistic capacity. Thus, confirmed cases are a suboptimal indicator of the extent of SARS-CoV-2 infection, and the magnitude of undiagnosed infections can vary widely [4]. SARS-CoV-2 seroprevalence studies are critical to monitor the epidemic evolution in a population and to inform public health measures, such as vaccine allocation [5]. Those studies estimate the number of past infections higher than the number of RT-PCR confirmed cases [6, 7]. In the case of an emergent agent, it is assumed that all population is initially susceptible; therefore, the presence of specific antibodies provides good estimates of the cumulative incidence particularly if the infection provides long-term serological immunity. In Portugal, the first case of coronavirus disease 2019 (COVID-19) was diagnosed on March 2, 2020 and on March 16 a nationwide schools closure was decreed affecting all education levels [8] – around 2 million students, more than 346 thousand from higher education [9]. Schools and universities fully reopened in mid-September 2020, providing an excellent opportunity to obtain data on the serum status of a large sample of university young adults exposed to highly varied risk contexts. This study aimed to estimate SARS-CoV-2 specific antibodies' seroprevalence and its determinants among students at the University of Porto (U.Porto), assessed between

METHODS AND PARTICIPANTS

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

All undergraduate and postgraduate students from the U.Porto were sent an email by the University communication office to invite them to perform a rapid serological test for SARS-CoV-2 specific immunoglobulin (Ig) M and IgG antibodies. Along with this email, an information leaflet was sent. Participation was voluntary, and students scheduled their appointment according to their convenience. They were invited to answer a face-to-face questionnaire conducted by the trained researcher who performed the test, while waiting for the result. The questionnaire included the following demographic and social questions: sex, age, living in usual residence (yes; no, usual residence in the country; no, usual residence abroad), faculty, history of contacts with a confirmed SARS-CoV-2 case since January 2020, history of being quarantined since January 2020, symptoms (then categorized as asymptomatic; paucisymptomatic: defined as having or having had one or two of the following symptoms: cough, dyspnea, odynophagia, headache, vomiting or nausea, diarrhea, fever, arthralgias, myalgia, asthenia; and symptomatic defined as having or having had at least three symptoms listed before, or dysgeusia or anosmia), ever being tested for SARS-CoV-2 infection, previous SARS-CoV-2 infection diagnosis, dates of diagnosis and recovery, self-perception of the probability of having been infected. Data reported in this study refer to the period between September 24 to December 15, 2020, during which 6512 students (approximately 20% of the 32,443 students of U.Porto) selfselected to have a point of care serological test. The participants' characteristics are presented in Table 1. The study protocol was approved by the ethics committee of the Institute of Public Health of the University of Porto (ID 20154). Verbal informed consent was obtained prior to the interview. Questionnaires were anonymous, and the results were only communicated to the

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

students. The identifying information needed to schedule testing was kept only at the U.Porto information systems' department. The linkage between datasets is impossible. SARS-CoV-2 specific IgM and IgG antibodies determination Three point-of-care tests were used according to the manufacturer instructions – the STANDARD Q COVID-19 IgM/IgG Combo (manufacturer reported sensitivity of 94.5% seven or more days after symptom onset and specificity of 95.7% for both IgG and IgM), the HIGHTOP -SARS-CoV-2 IgM/IgG Test Combo (manufacturer reported sensitivity of 82.0% and 93.0% and specificity of 96.0% and 97.5% for IgM and IgG, respectively), and the Teste Rápido Pantest de Coronavirus 2019-nCoV IgG/IgM (manufacturer reported sensitivity of 85.0% and 100% and specificity of 96.0% and 98.0% for IgM and IgG, respectively). The three manufacturers used RT-PCR as the gold standard. The first was used from September 24 to October 19 (n=2263), the second from October 19 to 26 (n=1059), and the third from October 27 onwards (n=3190). All participants presenting with symptoms or reporting high-risk contacts in the previous 14 days were recommended to contact the National Health Service Contact Center. All participants were communicated their results orally and also in the form of a written leaflet with the information that the serological test only indicates whether there is evidence of previous contact with the SARS-CoV-2 and that it cannot be used to diagnose or rollout SARS-CoV-2 infection. It also recommended that all SARS-CoV-2 preventive measures were to be adopted and to call the National Health Service Contact Center in case of symptoms. Statistical analysis We estimated seroprevalence as the proportion of individuals who had a reactive result in the IgM or IgG band of the point-of-care test. We estimated the true prevalence and 95% credible intervals (95% CI) using Bayesian inference. We used a uniform prior distribution for sensitivity ranging from 0.82 to 1 and specificity between 0.94 and 1. Estimates were obtained using the 'rjags' package in R.

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

Groups were compared using the Pearson Chi-Square, or the Fisher-exact test when the chisquare test's assumptions did not hold. **RESULTS** Table 1 presents the IgM, IgG and IgM or IgG apparent seroprevalence and reported SARS-CoV-2 infection prior diagnosis by a molecular test according to the characteristics of the U.Porto students. Among the 6512 students evaluated, 558 (8.6%) had a reactive test for IgM, 380 (5.8%) for IgG and 634 (9.7%) for IgM or IgG. The estimated true prevalence was 6.6 (95% CI 3.6-9.6) for IgM, 3.5 (95% CI 0.5-6.5) for IgG and 7.9 (95% CI 4.9-11.1) for IgM or IgG. The prevalence of IgG was higher among males (7.1% vs 5.3% among females, p=0.006). The prevalence of IgM or IgG antibodies was higher among the 30-34 years old and the 40 and more years old, 13.5% and 16.1%, respectively (vs 7.9 % in students under 20, 9.7% in 20-24 years, 10.9% in 25-29 years and 8.7% in 35-39 years, p=0.001). A history of prior diagnosis was also higher in those age groups, 2.5% among the 30-34 years old and 2.2% in those aged 40 years or over (vs 0.7% in students under 20, 1.5% in 20-24 years, 1.6% in 25-29 years and 1.6% in 35-39 years, p=0.028). The prevalence of antibodies was higher among international students (18.1% for IgM or IgG vs. 10.4% among those living in their usual family home and 8.8% among nationally displaced, p<0.001). The proportion of those who report a previous infection diagnosis was also higher among international students (3.8% vs 1.2% among those living in their usual family home and 1.0% among nationally displaced, p<0.001). Students who had contact with confirmed cases showed a prevalence of IgM or IgG of 20.5%, higher than the prevalence of 8.0% among those without (p<0.001). Similar results were found

among those who were quarantined (21.3% vs 8.3%, p<0.001). IgM or IgG prevalence was also

higher whenever there was a history of symptoms since the beginning of 2020, being 7.5%

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

among asymptomatic, 10.3% among paucisymptomatic and 20.1% among ever symptomatic students (p<0.001). SARS-CoV-2 infection had been previously diagnosed by a molecular test in 91 (1.4%) students. They had a prevalence of IgM or IgG antibodies of 86.8%; this was 10.7% in those tested negative and 8.1% in those never tested (p<0.001). Of the 91 (1.4%) students who had been previously diagnosed with SARS-CoV-2 infection, 48 (52.7%) had a diagnosis in October 2020. The distribution by month of diagnosis showed an increase in cases starting in August 2020. The prevalence of antibodies decreased with the increasing time since diagnosis, 76.9% among those diagnosed between two and five months and 68.4% among those diagnosed six or more months before the serological test. Among students without an infection diagnosis, the prevalence of antibodies increased with the increased perception of having been infected; it varied from 39.3% among those who considered this probability to be very high to 7.0% among those who thought it was low or very low. **DISCUSSION** The 6512 students had a 9.7% prevalence of IgM or IgG antibodies. However, only 1.4% reported a prior diagnosis of SARS-CoV-2 infection based on an RT-PCR result. The burden of infection in this group was 6.9 times higher than the reported cases considering the point estimate or 5.6 times higher if compared with the estimated true prevalence of 7.9%, as observed in previously published surveys [4, 6, 7, 10]. The lower true prevalence was expected. Even using high specificity and sensitivity tests there is a high number of false positives due to the relatively low frequency of infection in this population [11]. Students had a higher prevalence of infection than observed in the Portuguese serological survey (ISNCOVID-19), conducted between May and July 2020 (2.9%) [12]. Considering the participants in the age group 20-39 years both in the ISNCOVID-19 and the U.Porto students,

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

the prevalence was 2.9% and 10.1%, respectively. However, the studies were conducted in different periods of the epidemic in Portugal. The cumulative incidence of notified SARS-CoV-2 infection at the end of the national survey was 0.4% while at the end of this study, it was 3.5% [13]. These, along with differences in the recruitment of participants and the population's characteristics, explain the difference in results. Male and female students reported the same proportion of molecular diagnosis (1.4%). However, we found a higher seroprevalence among males, as reported in American university students [14], the Portuguese population [12] but not in other population-based surveys [4, 6, 7] and a meta-analysis [15]. We have no information on the study level (undergraduate or graduate) and therefore could not measure seroprevalence according to this variable, but older students had a higher seroprevalence. A previous study showed no difference in the prevalence of IgG antibodies in undergraduates and graduates suggesting they may have not had different lifestyles that would make them more or less susceptible [14] but considering age this may not have been the case in U.Porto. Students whose usual residence was abroad had a higher seroprevalence of infection. This might reflect a higher risk experience in their own countries or sharing a more vulnerable context during their stay in U.Porto. We found higher seroprevalence among students who reported previous negative molecular test compared with those never tested, suggesting that some RT-PCR results might have been false negatives [16]. In accordance with previous studies, the self-reported belief of having had SARS-CoV-2 infection, prior contact with confirmed cases, and having had symptoms were positively associated with a higher seroprevalence [7, 12, 14]. Despite a previous RT-PCR positive test, 17.6% showed no IgM and 13.2% IgG antibodies. These may be false negative results, evidence of no immune response, or more likely waning of antibodies over time. The observed decreasing seroprevalence with increasing time after the diagnosis also support this explanation, as previously described [17, 18]. However, it is

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

important to note that more than two-thirds of RT-PCR positive students had detectable immunological evidence of infection more than six months after diagnosis, indicating that antibodies may last long in a substantial proportion of individuals, as previously reported [19]. The national cumulative incidence of notified COVID-19 cases was 3.5% by the end of our data collection. However, only 1.4% of students reported a positive RT-PCR test for SARS-CoV-2. This lower incidence may be partially explained by the higher proportion of young people with few or no symptoms and, therefore, unnoticed infections, students' higher socioeconomic status, and an increased commitment to non-pharmacological preventive measures [1, 2]. It is worth mentioning that the number of reported cases among U.Porto students from September 16, 2020, to December 16, 2020, was 879, corresponding to 26 per 1000 students. This is almost double the observed in our sample and can have several explanations: 1. from an individual point of view those with previous infection may have less interest in doing the serological test because they know already they had contact with the virus; 2. they may be enrolled in care or having already an antibody test provided by the clinical services, and 3. some of those infections were recent and therefore students may have not yet had the opportunity to perform the test. We observed an increasing number of reported infection diagnosis in our study since August, as observed nationwide, but only one case in November, which might indicate that those diagnosed more recently did not yet have the chance to perform the test. We used three different point-of-care tests over three different periods. This was unintended and was due to manufacturer delay on delivery which are constraints of real-world research in a time of high demand. However, all tests presented similar manufacturer's reported characteristics, were used by the same trained researchers, and had similar performance in an in-house pilot test (data not shown). We cannot infer from this large sample to the U.Porto students' population due to the lack of representativeness and the relatively low participation,

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

probably explained by the voluntary nature of this testing program and the fact that many students remained on virtual learning. It is even possible that those who have had symptoms, high-risk contacts, or a self-perception of a higher probability of having been infected might be overrepresented. However, the dimension of infection in an educated, probably relatively lowrisk community, is strong evidence of the increasing burden of COVID-19 in Portugal. Conclusion In the University of Porto, students had a 7.9% seroprevalence, which was five times higher than the prevalence based on the reported molecular diagnoses and two times higher than the notified national cumulative incidence by the end of the study. Being an international student, reporting symptoms, self-perceiving high probability of infection, having had contact with a case, experiencing quarantine, and having had a diagnostic test performed though negative was associated with higher seroprevalence. Antibodies were present in 87% of those previously diagnosed with a molecular test, though reactivity decreased with increased time since the diagnosis. Funding: This study was funded by University of Porto and supported by national funds of Fundação para a Ciência e Tecnologia (FCT), under the scope of the project UIDB/04750/2020 -Research Unit of Epidemiology-Institute of Public Health of the University of Porto (EPIUnit). Joana Costa was the recipient of PhD grant 2020.08562.BD co-funded by the national funds of FCT and the Fundo Social Europeu (FSE). The funding source had no role in the work. Acknowledgements: We wish to acknowledge the team of researchers in the field namely Ana Margarida Lopes, Daniela Soares, Ema Fortunato, Flávia Mouta, Inês Roque, Inês Teixeira, Jacinta Mendonça, Janessa Oliveira, Laís Vieira, Mafalda Alves, Marta Costa, and Suellen Brito. The IT support from Paulo Oliveira, Celeste Pinto and Elisabete Neves. The U.Porto communication team led by Raul Santos. The U.Porto vice-rector Pedro Rodrigues.

- 231 Competing interests: The authors have no conflicts of interest to declare that are relevant to
- 232 the content of this article.
- 233 Availability of data and material: The datasets generated during and/or analyzed during the
- 234 current study are available from the corresponding author on reasonable request.
- 235 Ethics approval: This study was performed in line with the principles of the Declaration of
- 236 Helsinki. The study protocol was approved by the ethics committee of the Institute of Public
- 237 Health of the University of Porto (ID 20154).
- 238 Consent to participate: Verbal informed consent was obtained prior to the interview.

REFERENCES

- 241 Felsenstein S, Hedrich CM (2020) SARS-CoV-2 infections in children and young people. [1]
- 242 Clinical Immunology 220:108588
- 243 [2] Oran DP, Topol EJ (2020) Prevalence of Asymptomatic SARS-CoV-2 Infection. Annals of
- 244 Internal Medicine 173 (5):362-367
- 245 [3] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. (2020) Risk factors for severity and mortality
- 246 in adult COVID-19 inpatients in Wuhan. Journal of Allergy and Clinical Immunology 146 (1):110-
- 247 118

239

240

- 248 [4] Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. (2020) Seroprevalence
- 249 of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA
- 250 Internal Medicine 180 (12):1576-1586
- 251 [5] World Health Organization (WHO). Population-based age-stratified seroepidemiological
- 252 investigation protocol for coronavirus 2019 (COVID-19)infection (version 2.0). World Health
- 253 Organization, Geneva
- 254 Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. (2020)
- 255 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a
- 256 population-based study. The Lancet 396 (10247):313-319
- 257 [7] Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al.
- 258 (2020) Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based
- 259 seroepidemiological study. The Lancet 396 (10250):535-544

- [8] Presidência do Conselho de Ministros (2020) Decreto-Lei n.º 10-A/2020: Diário da 260
- 261 República n.º 52/2020, 1º Suplemento, Série I de 2020-03-13.
- 262 [9] UNESCO (2020) COVID-19 Impact on Education: Global monitoring of school closures
- 263 caused by COVID-19, https://en.unesco.org/covid19/educationresponse. Cited 27 december
- 264 2020
- Rogawski McQuade ET, Guertin KA, Becker L, Operario D, Gratz J, Guan D, et al. (2021) 265 [10]
- 266 Assessment of Seroprevalence of SARS-CoV-2 and Risk Factors Associated With COVID-19
- 267 Infection Among Outpatients in Virginia. JAMA Network Open 4 (2):e2035234-e2035234
- 268 Kumleben N, Bhopal R, Czypionka T, Gruer L, Kock R, Stebbing J, et al. (2020) Test, test,
- 269 test for COVID-19 antibodies: the importance of sensitivity, specificity and predictive powers.
- 270 Public Health 185:88-90
- 271 [12] Kislaya I, Gonçalves P, Barreto M, de Sousa R, Garcia AC, Matos R, et al. (2021)
- 272 Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First
- 273 National Serological Survey (ISNCOVID-19). 2021 34 (2):8
- 274 [13] (2020) Direção Geral da Saúde (DGS). COVID-19 | Relatório de Situação nº 289 | 16
- 275 dezembro 2020.
- 276 Tilley K, Ayvazyan V, Martinez L, Nanda N, Kawaguchi ES, O'Gorman M, et al. (2020) A [14]
- 277 Cross-Sectional Study Examining the Seroprevalence of Severe Acute Respiratory Syndrome
- 278 Coronavirus 2 Antibodies in a University Student Population. J Adolesc Health 67 (6):763-768
- 279 [15] Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M,
- 280 Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-
- 281 analysis. Clinical Microbiology and Infection
- Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, Del 282 [16]
- 283 Campo R, Ciapponi A, et al. (2020) False-negative results of initial RT-PCR assays for COVID-19:
- 284 A systematic review. PLoS One 15 (12):e0242958
- 285 Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. (2021) [17]
- Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLOS ONE 15 286
- 287 (12):e0244126

- 288 Sethuraman N, Jeremiah SS, Ryo A (2020) Interpreting Diagnostic Tests for SARS-CoV-2. [18]
- 289 JAMA 323 (22):2249-2251
- 290 Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. (2021) Immunological
- 291 memory to SARS-CoV-2 assessed for up to 8 months after infection. Science:eabf4063

Table 1: Characteristics of participants, IgM, IgG and IgM or IgG apparent seroprevalence and reported SARS-CoV-2 infection diagnosis by a molecular test according to those characteristics among U.Porto students from September to December 2020, Porto, Portugal

		Total of participants		IgM seroprevalence	IgG seroprevalence	IgM or IgG seroprevalence	Prior SARS-CoV-2 infection diagnosis
		N	%	N (%)	N (%)	N (%)	N (%)
Overall		6512	100	558 (8.6)	380 (5.8)	634 (9.7)	91 (1.4)
SOCIODEMOGRAPHIC CHARACTERISTICS							
Sex							
Female		4554	69.9	8.1	5.3	9.2	1.4
Male		1951	30.0	9.6	7.1	10.9	1.4
Missing		7	0.1				
	p-value			0.060	0.006	0.048	0.907
Age strata (years)							
< 20		1600	24.6	6.8	4.3	7.9	0.7
20-24		3548	54.5	8.7	5.7	9.7	1.5
25-29		735	11.3	10.1	7.2	10.9	1.6
30-34		319	4.9	10.7	10.0	13.5	2.5
35-39		127	2.0	7.1	5.5	8.7	1.6
>= 40		180	2.8	14.4	10.6	16.1	2.2
Missing		3	0.0				
	p-value			0.002	<0.001	0.001	0.028
Living in usual residency							
Yes		3689	56.6	7.7	5.1	10.4	1.2
No, but usual residence in the country		2192	33.7	7.9	4.7	8.8	1.0
No, usual residence abroad		626	9.6	15.8	14.4	18.1	3.8
Missing		5	0.1				
-	p-value			<0.001	<0.001	<0.001	<0.001
INFECTION-RELATED CHARACTERISTICS							
Previous RT-PCR test and diagnosis							
Never tested		5062	77.7	7.0	4.2	8.1	
Tested, not diagnosed		1358	20.9	9.6	6.8	10.7	
Tested, diagnosed		91	1.4	82.4	84.6	86.8	

Missing		1	0.0				
-	p-value			<0.001	<0.001	<0.001	
Confirmed case contact							
No	50	624	86.4	7.1	4.0	8.0	0.5
Yes	8	878	13.5	17.8	17.3	20.5	7.3
Missing	:	10	0.2				
	p-value			< 0.001	<0.001	< 0.001	< 0.001
Quarantined							
No	5	757	88.4	7.2	4.3	8.3	0.4
Yes	7	748	11.5	19.0	17.4	21.3	9.0
Missing		7	0.1				
	p-value			<0.001	<0.001	<0.001	<0.001
Symptoms since January 2020							
Asymptomatic	4	871	74.8	6.6	3.7	7.5	0.4
Paucissymptomatic ¹	6	689	10.6	9.9	6.5	10.4	1.5
Symptomatic ¹	g	947	14.5	17.5	16.4	20.5	6.3
Missing		5	0.1				
	p-value			<0.001	<0.001	<0.001	<0.001
Self-perception of the probability of having alread	ly been infected						
* (excluding those with diagnosis n= 6421)							
Very low	8	860	13.2	6.2	3.5	7.0	
Low	3:	134	48.1	6.3	3.1	7.0	
Moderate	19	.954	30.0	7.8	4.9	8.9	
High	3	351	5.4	14.0	12.0	16.2	
Very high	1	117	1.8	28.2	33.3	39.3	
Missing		5	0.1				
	p-value			<0.001	<0.001	<0.001	
Previous RT-PCR test and diagnosis							
Never tested	50	062	77.7	7.0	4.2	8.1	
Tested, not diagnosed	1	.358	20.9	9.6	6.8	10.7	
Tested, diagnosed	9	91	1.4	82.4	84.6	86.8	
Missing		1	0.0				
	p-value			<0.001	< 0.001	<0.001	

Time sin	ce the diagnosis	(among those	previously	diagnosed n	=
91)					
	. 4 4 1				

< 14 days	2	2.2%	100.0%	100.0%	100.0%
14-29 days	24	26.4%	87.5%	83.3%	87.5%
30 days-2months	33	36.3%	100.0%	97.0%	100.0%
2-5 months	13	14.3%	61.5%	76.9%	76.9%
>= 6 months	19	20.9%	57.9%	68.4%	68.4%
Missing	0	0.0%			
	p-value		<0.001*	0.044*	0.005
Month of diagnosis (among those previously diag	gnosed n= 91)				
March	9	9.9%	55.6%	66.7%	66.7%
April	9	9.9%	66.7%	77.8%	77.8%
May	3	3.3%	66.7%	66.7%	66.7%
June	0	0.0%	-	-	-
July	1	1.1%	0.0%	0.0%	0.0%
August	8	8.8%	75.0%	75.0%	75.0%
September	12	13.2%	83.3%	83.3%	100.0%
October	48	52.7%	93.8%	93.8%	93.8%
November	1	1.1%	100.0%	100.0%	100.0%
Missing	9	9.9%			
	p-value		0.008*	0.033*	0.012*

¹ Paucisymptomatic: having or having had one or two of the following symptoms: cough, dyspnea, odynophagia, headache, vomiting or nausea, diarrhea, fever, arthralgias, myalgia, asthenia; Symptomatic defined as having or having had at least three symptoms listed before, or dysgeusia or anosmia.

^{*}P-value for the Fisher exact-test